NGF and Parkinson disease: Furthermore, PACA was found to increase the conversion of proNGF to active NGF in the midbrain and to sequentially activate the PI3K/Akt, Erk, and CREB signaling pathways, suggesting it as a potent drug candidate for the protection of dopaminergic neurons against neurodegeneration in PD [109].